Managing hypoandrogenism in prostate cancer patients

Prior to the mid-1980s, ADT was used predominantly in symptomatic men with metastatic disease but now it is also used in asymptomatic metastatic disease.

In addition, ADT is used as a primary therapy in men with localised disease deemed unfit for surgery or radiotherapy; as an adjunct treatment in men with high risk prostate cancer treated with radiotherapy or those with nodal disease proven at radical prostatectomy; and, as a salvage therapy in men who biochemically fail surgery or radiotherapy for presumed